Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy

Abstract Background Ectopic pregnancy is a major life- and fertility-threatening women’s health concern. As a result of advances in examination technology, an increasing number of ectopic pregnancies can be diagnosed early and treated with medical methods instead of surgery. The aim of this study wa...

Full description

Bibliographic Details
Main Authors: Jing Zhang, Yu Zhang, Lu Gan, Xiao-ying Liu, Shan-ping Du
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Pregnancy and Childbirth
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12884-020-03350-8
_version_ 1818317947393802240
author Jing Zhang
Yu Zhang
Lu Gan
Xiao-ying Liu
Shan-ping Du
author_facet Jing Zhang
Yu Zhang
Lu Gan
Xiao-ying Liu
Shan-ping Du
author_sort Jing Zhang
collection DOAJ
description Abstract Background Ectopic pregnancy is a major life- and fertility-threatening women’s health concern. As a result of advances in examination technology, an increasing number of ectopic pregnancies can be diagnosed early and treated with medical methods instead of surgery. The aim of this study was to summarize the clinical features and identify the predictors of success of methotrexate (MTX) treatment of ectopic pregnancy. Methods This was a retrospective study of 238 ectopic pregnancies treated with MTX in the Department of Gynecology of Shaanxi Provincial People’s Hospital from January 2017 to December 2017. Results Patients were divided into two groups: the successful treatment group (n = 166) and the failed treatment group (n = 72). The overall success rate of MTX therapy for ectopic pregnancy was 69.75%. The mean initial beta-human chorionic gonadotropin (β-hCG) level was significantly lower in the successful treatment group than in the failed treatment group (2538.08 IU/L versus 3533.17 IU/L, P = 0.000). The treatment success rate of the group with an initial β-hCG concentration less than 4000 IU/L was significantly higher than that of the group with an initial β-hCG concentration greater than 4000 IU/L. However, the success rate of the group with an initial β-hCG concentration greater than 4000 IU/L was still relatively high (54.55%). β-hCG levels were significantly increased on the 4th day in the failed treatment group (P = 0.000). Compared to the initial β-hCG level, the day-4 β-hCG level increased by more than 8.21%, indicating that the treatment was effective. The diagnostic sensitivity was 88.6%, the specificity was 74.5%, and the area under the receiver operating characteristic (ROC) curve was 0.863 (95% confidence interval (CI): 0.805–0.920). Conclusions MTX therapy as a treatment option is safe and effective for asymptomatic, hemodynamically stable patients with ectopic pregnancies who are interested in conservative treatment, regardless of the serum β-hCG level or adnexal mass size. The change in the β-hCG level between the initial day and the 4th day is an effective and early predictive tool for the success of MTX therapy for ectopic pregnancy.
first_indexed 2024-12-13T09:45:25Z
format Article
id doaj.art-7b72423fed6e49049ac116805a2b75cc
institution Directory Open Access Journal
issn 1471-2393
language English
last_indexed 2024-12-13T09:45:25Z
publishDate 2020-10-01
publisher BMC
record_format Article
series BMC Pregnancy and Childbirth
spelling doaj.art-7b72423fed6e49049ac116805a2b75cc2022-12-21T23:52:05ZengBMCBMC Pregnancy and Childbirth1471-23932020-10-012011910.1186/s12884-020-03350-8Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancyJing Zhang0Yu Zhang1Lu Gan2Xiao-ying Liu3Shan-ping Du4Shaanxi Provincial People’s HospitalShaanxi Provincial People’s HospitalShaanxi Provincial People’s HospitalShaanxi Provincial People’s HospitalShaanxi Provincial People’s HospitalAbstract Background Ectopic pregnancy is a major life- and fertility-threatening women’s health concern. As a result of advances in examination technology, an increasing number of ectopic pregnancies can be diagnosed early and treated with medical methods instead of surgery. The aim of this study was to summarize the clinical features and identify the predictors of success of methotrexate (MTX) treatment of ectopic pregnancy. Methods This was a retrospective study of 238 ectopic pregnancies treated with MTX in the Department of Gynecology of Shaanxi Provincial People’s Hospital from January 2017 to December 2017. Results Patients were divided into two groups: the successful treatment group (n = 166) and the failed treatment group (n = 72). The overall success rate of MTX therapy for ectopic pregnancy was 69.75%. The mean initial beta-human chorionic gonadotropin (β-hCG) level was significantly lower in the successful treatment group than in the failed treatment group (2538.08 IU/L versus 3533.17 IU/L, P = 0.000). The treatment success rate of the group with an initial β-hCG concentration less than 4000 IU/L was significantly higher than that of the group with an initial β-hCG concentration greater than 4000 IU/L. However, the success rate of the group with an initial β-hCG concentration greater than 4000 IU/L was still relatively high (54.55%). β-hCG levels were significantly increased on the 4th day in the failed treatment group (P = 0.000). Compared to the initial β-hCG level, the day-4 β-hCG level increased by more than 8.21%, indicating that the treatment was effective. The diagnostic sensitivity was 88.6%, the specificity was 74.5%, and the area under the receiver operating characteristic (ROC) curve was 0.863 (95% confidence interval (CI): 0.805–0.920). Conclusions MTX therapy as a treatment option is safe and effective for asymptomatic, hemodynamically stable patients with ectopic pregnancies who are interested in conservative treatment, regardless of the serum β-hCG level or adnexal mass size. The change in the β-hCG level between the initial day and the 4th day is an effective and early predictive tool for the success of MTX therapy for ectopic pregnancy.http://link.springer.com/article/10.1186/s12884-020-03350-8Ectopic pregnancyMTX therapyβ-hCG
spellingShingle Jing Zhang
Yu Zhang
Lu Gan
Xiao-ying Liu
Shan-ping Du
Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
BMC Pregnancy and Childbirth
Ectopic pregnancy
MTX therapy
β-hCG
title Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
title_full Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
title_fullStr Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
title_full_unstemmed Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
title_short Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
title_sort predictors and clinical features of methotrexate mtx therapy for ectopic pregnancy
topic Ectopic pregnancy
MTX therapy
β-hCG
url http://link.springer.com/article/10.1186/s12884-020-03350-8
work_keys_str_mv AT jingzhang predictorsandclinicalfeaturesofmethotrexatemtxtherapyforectopicpregnancy
AT yuzhang predictorsandclinicalfeaturesofmethotrexatemtxtherapyforectopicpregnancy
AT lugan predictorsandclinicalfeaturesofmethotrexatemtxtherapyforectopicpregnancy
AT xiaoyingliu predictorsandclinicalfeaturesofmethotrexatemtxtherapyforectopicpregnancy
AT shanpingdu predictorsandclinicalfeaturesofmethotrexatemtxtherapyforectopicpregnancy